Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma (NCT04468841) | Clinical Trial Compass
Active — Not RecruitingPhase 1
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
United States77 participantsStarted 2020-07-08
Plain-language summary
The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to understand how different genetic changes in follicular lymphoma relate to a person's response to the usual first-line treatment.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ≥18 years of age at time of signing informed consent. Consent is permitted from either the participant or from a Legally Authorized Representative (LAR) on their behalf.
* Histology-confirmed follicular lymphoma grade 1-3a, verified by the enrolling institution
* Ability to adhere to the study visit schedule and all the protocol requirements
* Measurable FDG-avid disease
* Not applicable for retrospective patients in CR
Exclusion Criteria:
* Patients receiving second or greater line of therapy (except in retrospective cohort of long-term survivors of FL \[i.e. \>10 years out from frontline treatment\])
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is focused on testing whether a blood-based cell-free DNA assay can detect follicular lymphoma — it's not testing a new treatment, so what would participating actually involve for me, and could it affect my current care plan in any way?
2Since this is a Phase 1 study primarily checking whether the cfDNA test can accurately detect disease, what does that mean for what we'd actually learn about my individual situation, and would the results be shared with us or used to guide my treatment?
3The trial is no longer recruiting new patients — is there any way to find out if a similar or follow-up study is open that might give me access to this kind of liquid biopsy monitoring for follicular lymphoma?
4How does measuring cell-free DNA compare to the imaging or biopsy methods already used to track my follicular lymphoma, and is this something my care team is already exploring outside of a clinical trial?
5Given that follicular lymphoma can have an indolent course for some patients, would participating in a study like this — even just for monitoring purposes — be worth discussing now, or is it more relevant at a specific stage of my disease?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
whether the assay can correctly identify presence of disease in patients with measurable disease